Skip to main content
Terug
CMOPF logo

Cosmo Pharmaceuticals N.V.

Datakwaliteit: 100%
CMOPF
OTC Healthcare Drug Manufacturers - General
€ 102,31
▼ € 0,62 (-0,60%)
Marktkapitalisatie: 1,66B
Dagbereik
€ 97,00 € 102,31
52-Weeksbereik
€ 55,00 € 169,90
Volume
200
50D / 200D Gem.
€ 140,81 / € 98,97
Vorige Slotkoers
€ 102,93

Quick Summary

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (633 peers)

Metriek Aandeel Sector Mediaan
P/E -456,3 0,2
P/B 3,4 2,8
ROE % -0,7 3,7
Net Margin % -3,5 3,9
Rev Growth 5Y % 12,7 10,0
D/E 0,0 0,2

Koersdoel Analisten

Geen analistendekking beschikbaar

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2030 € 20,60
€ 14,94 – € 35,33
 407,25M 1
FY2029 € 6,87
€ 4,98 – € 11,78
 288,77M 1
FY2028 € 3,38
€ 2,45 – € 5,80
 200,89M 1

Earnings Surprises

Last 8 quarters
Quarter Est. EPS Actual EPS Surprise
2026-03-09 -€ 0,02 -€ 0,12 -402,3%
2025-07-23 N/A -€ 0,15 —
2025-03-06 N/A € 3,61 —
2024-07-24 N/A € 5,06 —
2024-05-24 N/A -€ 0,44 —
2023-06-30 N/A € 0,10 —
2022-12-31 N/A € 0,62 —
2022-06-30 N/A € 0,50 —

Dividend History

4 yr streak

Yield

0,02%

Payout Ratio

-9,06%

Growth (3Y)

32,37%

Growth (5Y)

N/A

Ex-Date Payment Date Amount Yield
Apr 24, 2026 May 11, 2026 € 1,57 1,54%
Jun 05, 2025 Jun 06, 2025 € 2,35 3,73%
Jul 11, 2024 Jul 12, 2024 € 2,17 2,92%
May 31, 2023 Jun 02, 2023 € 1,12 2,20%
Jun 01, 2022 Jun 03, 2022 € 1,01 2,34%
May 29, 2017 May 31, 2017 € 1,68 2,01%
Aug 31, 2016 Sep 15, 2016 € 1,56 0,97%

Belangrijkste Punten

Revenue grew 12,66% annually over 5 years — strong growth
Earnings declined -102,72% over the past year
Debt/Equity of 0,01 — conservative balance sheet
Negative free cash flow of -15,84M
Revenue growth is decelerating — 1Y growth trails 5Y average by 73,37%
Capital efficient — spends only 4,04% of revenue on capex

Groei

Revenue Growth (5Y)
12,66%
Revenue (1Y)-60,71%
Earnings (1Y)-102,72%
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-0,74%
ROIC-1,62%
Net Margin-3,46%
Op. Margin-10,00%

Veiligheid

Debt / Equity
0,01
Current Ratio7,18
Interest Coverage-57,54

Waardering

P/E Ratio
-456,27
Forward P/E1096,06
P/B Ratio3,44
EV/EBITDAN/A
Dividend Yield0,02%

All Fundamental Metrics

Growth
Revenue Growth (1Y) -60,71% Revenue Growth (3Y) 6,29%
Earnings Growth (1Y) -102,72% Earnings Growth (3Y) N/A
Revenue Growth (5Y) 12,66% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 104,82M Net Income (TTM) -3,63M
ROE -0,74% ROA -0,59%
Gross Margin 46,53% Operating Margin -10,00%
Net Margin -3,46% Free Cash Flow (TTM) -15,84M
ROIC -1,62% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,01 Current Ratio 7,18
Interest Coverage -57,54
Dividends
Dividend Yield 0,02% Payout Ratio -9,06%
Dividend Growth (3Y) 32,37% Dividend Growth (5Y) N/A
Consecutive Div Years 4 yrs
Valuation
P/E Ratio -456,27 Forward P/E 1096,06
P/B Ratio 3,44 P/S Ratio 15,80
PEG Ratio 4,84 Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA 46,36
Forward P/S 15,19 Fwd Earnings Yield 0,09%
FCF Yield -0,96%
Market Cap 1,66B Enterprise Value 1,60B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 104,82M 266,79M 92,78M 102,09M 65,07M
Net Income -3,63M 133,24M -4,93M 17,23M 21,67M
EPS (Diluted) -0,23 8,12 -0,31 1,05 1,28
Gross Profit 48,77M 246,92M 53,44M 83,33M 49,93M
Operating Income -10,48M 148,88M 6,15M 28,06M 11,10M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 611,97M 646,77M 553,98M 759,59M 805,56M
Total Liabilities 123,32M 141,68M 124,94M 295,80M 292,88M
Shareholders' Equity 481,78M 498,33M 422,16M 456,93M 505,28M
Total Debt 4,26M 2,20M 1,84M 173,60M 169,92M
Cash & Equivalents 55,80M 44,30M 50,28M 185,83M 198,56M
Current Assets 183,08M 202,26M 102,23M 306,10M 275,85M
Current Liabilities 25,49M 48,27M 25,71M 194,95M 21,24M